Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SGMO vs IMMX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMMX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–4 Matrix Metrics)

IMMX Overall Winner 6-Pillar Tally: SGMO 2 – 3 IMMX (1 Tie) Matrix Metrics: SGMO 4 – 5 IMMX

As of Nov 16, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over Sangamo Therapeutics, Inc. (SGMO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SGMO carries a Unified Composite Score of 52.0/100 (HOLD) at $0.18 (0.4x Forward P/E, -175.5% operating margin), whereas IMMX carries 48.6/100 (HOLD) at $7.59 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While SGMO currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. IMMX 48.6/100 HOLD), IMMX captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -175.5% operating margin) and revenue trajectory (+0.0% vs. +88.4% YoY).
  • Technical & Structure Timing Caution: SGMO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SGMO vs IMMX
SGMO NASDAQ
Sangamo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.18
+31.56% 1D
Market Cap $55.9M
TTM Revenue $40M
Forward P/E 0.4x
Beta / 30D Vol 1.49β · 206% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.4%), weak momentum, RSI 38
RSI-14: 38.4 · SMA20: $0.23 · SMA50: $0.31
IMMX NASDAQ Head-to-Head Winner
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$7.59
-3.19% 1D
Market Cap $655.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.80β · 84% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 46.0 Fund 55.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 41
RSI-14: 40.7 · SMA20: $8.05 · SMA50: $9.69

6-Pillar Scorecard Institutional Category Breakdown (SGMO 2 – 3 IMMX)

Columns: Metric · SGMO · IMMX
1. Valuation Multiples SGMO
Forward P/E 0.4x N/M
Trailing P/E 0.4x N/M
PEG Ratio N/M N/M
EV / Revenue 1.2x N/M
2. Growth & Scale SGMO
Revenue Growth (YoY) +88.4% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $40M N/A
Market Cap $55.9M $655.8M
3. Profitability & Quality IMMX
Gross Margin N/A N/A
Operating Margin -175.5% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -2891.8% -27.0%
4. Balance Sheet & Cash Flow IMMX
Cash Generation (TTM) -$90M -$39M
Cash Flow Margin N/A N/A
Net Cash / Leverage $8.3M Net Cash $224M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IMMX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 144.2% (71st %ile) 92.6% (17th %ile)
Put/Call OI Skew N/A 1.24x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SGMO (4) vs IMMX (5)
Institutional Metric SGMO IMMX Criterion Row Edge
Market Capitalization
Scale
$55.9M $655.8M Larger Scale IMMX
Trailing P/E Ratio
Valuation
0.4x N/M Lower Multiple SGMO
Forward P/E Ratio
Valuation
0.4x N/M Lower Multiple SGMO
Revenue Growth (YoY)
Growth
+88.4% +0.0% Higher Growth SGMO
Operating Margin (TTM)
Profitability
-175.5% 0.0% Higher Margin IMMX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-2891.8% -27.0% Higher ROE IMMX
52-Week Range Position
Momentum
9% ($0–$1) 36% ($3–$15) Stronger Trend IMMX
Beta / 30D Volatility
Risk Regime
1.49β · 206% Vol 1.80β · 84% Vol Lower Realized Risk IMMX
Unified Institutional Score
Composite Signal
52.0 / 100 (HOLD) 48.6 / 100 (HOLD) Higher Composite SGMO
Trailing 12M Revenue (USD)
Operating Scale
$40M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$90M ($8.3M Net Cash) -$39M ($224M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IMMX +46.86 pp
SGMO: -40.82% · IMMX: +6.04%
3M Horizon IMMX +121.39 pp
SGMO: -68.73% · IMMX: +52.66%
6M Horizon IMMX +223.06 pp
SGMO: -60.46% · IMMX: +162.6%
1Y Horizon IMMX +223.06 pp
SGMO: -60.46% · IMMX: +162.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SGMO vs IMMX. Trailing 12-month operating profitability (SGMO -175.5% vs IMMX 0.0%) and valuation multiples (SGMO 0.4x vs IMMX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SGMO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40M
Gross MarginN/A
Op. Margin-175.5%
ROE / Fwd P/E-2891.8% · 0.4x
IMMX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-27.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SGMO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 144.2%
IV Percentile 71st %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SGMO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IMMX BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 92.6%
IV Percentile 17th %ile
Put/Call OI Skew 1.24x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact IMMX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SGMO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $55.9M market capitalization and -175.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IMMX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $655.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SGMO vs IMMX Key Questions & Quantitative Answers

As of Nov 16, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over Sangamo Therapeutics, Inc. (SGMO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SGMO carries a Unified Composite Score of 52.0/100 (HOLD) at $0.18 (0.4x Forward P/E, -175.5% operating margin), whereas IMMX carries 48.6/100 (HOLD) at $7.59 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While SGMO currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. IMMX 48.6/100 HOLD), IMMX captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -175.5% operating margin) and revenue trajectory (+0.0% vs. +88.4% YoY). Technical & Structure Timing Caution: SGMO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SGMO leads the Growth & Scale pillar: SGMO posts +88.4% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (N/A gross margin, -175.5% operating margin), compared with IMMX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SGMO generates $40M in USD-normalized revenue versus N/A for IMMX. In operating R&D and SG&A reinvestment, SGMO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMMX.

SGMO screens cheaper on headline valuation multiples. SGMO trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and 1.2x EV/Revenue (unreported FCF margin), whereas IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGMO (-2891.8% ROE) versus IMMX (-27.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SGMO carries 144.2% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.49β · 206% Vol realized risk). By comparison, IMMX carries 92.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.24x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.80β · 84% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.